Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > These are big days coming up
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Sep 21, 2021 12:26pm
127 Views
Post# 33892538

RE:These are big days coming up

RE:These are big days coming up
Amigo11 wrote: Time for ATE news and discussions,not the general Grade 3 garbage that this post has become the host of .Pull it together folks!I think we all want to figure out what's going on!


Amigo! ... we wait for October!

I'm going to hope that they are moving faster than the markets expect - ideally already applied for AME #2 or other related studies.  I would appreciate more than just an update on findings and a plan forward.  I'd like to know where they are in that plan forward.  With cash-in-hand ... money needs to be put to work quickly in this kind of situation. IMO.

Here's to hoping ... but ... we are in waiting pattern.

During this time, some have divested, some are adding and some are sitting still with what they have.  Heck, I'm sure some never even had a share.

We have all kinds here ... choosing their own strategy forward.

Happy Hydrogen Sulfide Games and may the odds be ever in your favor.”

: )
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities